Animal studyReported positivePreclinical onlyTier 2 · animal
Molecular cancer therapeutics · Sep 2026
This preclinical study tested a novel CDK12 inhibitor (CTX-439) alone and combined with the PARP inhibitor olaparib in uterine serous carcinoma (USC) cell lines and patient-derived xenograft models. CTX-439 suppressed expression of HR-related genes (including BRCA1 and BRCA2), induced DNA damage and apoptosis, inhibited tumor growth in PDX models with high CDK12 expression, and enhanced tumor sensitivity to olaparib. Analysis of genomic datasets found CDK12 amplification more frequent in USC than in high-grade serous ovarian carcinoma, associated with higher CDK12 expression and poorer prognosis, but not with HRD scores.
Studied with: olaparib.
Key findings
- USC exhibited a higher HRD score than other histologic subtypes of uterine endometrial carcinoma but lower than HGSOC.
- CDK12 amplification occurred more frequently in USC than in HGSOC but was not associated with HRD scores.
- Tumors with CDK12 amplification demonstrated high CDK12 expression, which correlated with poor prognosis in USC.
- The CDK12 inhibitor CTX-439 suppressed HR-related gene expression, including BRCA1 and BRCA2.
- CTX-439 induced apoptosis and DNA damage in USC models.
- CTX-439 inhibited tumor growth in USC PDX models with high CDK12 expression.
- CDK12 inhibition enhanced tumor sensitivity to the PARP inhibitor olaparib in USC PDX models.
Limitations: Preclinical study limited to cell lines and patient-derived xenograft (PDX) models; no human clinical data presented.; Abstract does not report sample sizes, dosing regimens, or toxicity/safety data.; No long-term outcomes or survival data in patients.; Findings from PDX models may not translate to clinical efficacy in humans..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
Cureus · May 2026 · case report
endometrial serous carcinomauterine serous carcinoma
This paper is a case report of a postmenopausal woman diagnosed with endometrial (uterine) serous carcinoma that arose from adenomyosis. The authors describe diagnostic challenges, clinical management, and prognosis for this single patient and include a literature review to provide broader context.
Key findings
- Reported a single case of uterine/ endometrial serous carcinoma arising from adenomyosis.
- Highlights diagnostic challenges when serous carcinoma is associated with adenomyosis.
- Discusses clinical management and prognosis for the reported patient.
- Includes a comprehensive review of the literature on this uncommon association.
Limitations: Single-patient case report limits generalizability.; No quantitative outcomes or comparative data reported.; No mechanistic or pathological detail provided in the abstract.; Prognostic implications cannot be inferred from one case..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 94
American journal of epidemiology · Jan 2026 · retrospective cohort study
uterine serous carcinoma
This retrospective single-institution study identified 94 patients with stage I–II uterine serous carcinoma treated from 2006–2019 and examined associations between adjuvant therapies and outcomes. Most patients received adjuvant therapy, commonly chemotherapy plus vaginal brachytherapy; at median follow-up 33.5 months, 81.9% had no evidence of disease. Patients receiving six cycles of adjuvant chemotherapy had statistically better overall survival (P = .004) and recurrence-free survival (P = .02) compared with those who did not receive adjuvant chemotherapy.
Reported effects: sample_size 94, n=94 · median_followup 33.5 mo, n=94 · +10 more
Studied with: radiation therapy, vaginal brachytherapy.
Key findings
- Ninety-four patients were identified.
- Median follow-up time was 33.5 months.
- Median age was 68 years (range, 49-87).
- Most patients (n = 79, 84.0%) received adjuvant therapy; a majority received a combination of systemic chemotherapy and radiation therapy (n = 55, 58.5%), with chemotherapy plus vaginal brachytherapy the most common combination (n = 42, 44.7%).
- Most patients (n = 77, 81.9%) remained without evidence of disease, while 17 patients (18.1%) recurred.
- Patients receiving 6 cycles of adjuvant chemotherapy experienced improved overall survival (P = .004) and improved recurrence-free survival (P = .02) compared to those receiving no adjuvant chemotherapy.
Limitations: Retrospective, non-randomized design; Single-institution cohort; Relatively small sample size (n = 94); Potential selection and treatment-allocation bias; Median follow-up of 33.5 months is modest and may limit assessment of long-term outcomes; No chemotherapy regimen details or toxicity data provided in the abstract.
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
Journal of ultrasound · Nov 2025 · case report
uterine serous carcinomaendometrial cancer arising in adenomyosisendometrial carcinoma
This is a case report of a 55-year-old postmenopausal woman who was found to have uterine serous carcinoma arising in adenomyosis. Imaging (CT and ultrasound) showed pelvic cystic masses and a 50 × 36 mm subserous cystic-solid uterine mass that was initially misdiagnosed as a degenerating fibroid; postoperative histopathology established the diagnosis. The authors note that a de novo cystic area in adenomyosis in postmenopausal women may suggest malignant transformation and emphasize ultrasound as the first imaging choice for gynecological masses.
Reported effects: CA125 44.86, n=1 · tumor_size, n=1
Key findings
- A 55-year-old postmenopausal woman presented with anorexia, weight loss and mild abdominal pain; pelvic CT showed cystic masses.
- Serum CA125 was 44.86 u/ml.
- Transvaginal/transabdominal ultrasound detected a 50 × 36 mm subserous cystic-solid mass that was misdiagnosed preoperatively as a subserous uterine fibroid with cystic degeneration.
- Postoperative histopathological diagnosis was uterine serous carcinoma arising from adenomyosis.
- Authors suggest that a de novo cystic area in adenomyosis in postmenopausal women may indicate malignant transformation and present ultrasound images to raise diagnostic awareness.
Limitations: Single case report (n=1), so findings are not generalizable.; No control or comparison group.; Abstract provides limited pathological, immunohistochemical, and follow-up details.; Imaging features described may be nonspecific and susceptible to misdiagnosis.; No data on prevalence, diagnostic performance metrics, or outcomes beyond the single case..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMechanismInconclusiveLimited evidenceTier 3 · early human
Cells · Aug 2025 · review
uterine serous carcinomaendometrial cancerbreast cancer
This is a narrative review of HER2/neu as a signaling and therapeutic marker in uterine serous carcinoma (USC). It summarizes HER2 expression and amplification in USC, compares USC HER2 features to breast cancer, evaluates preclinical and clinical evidence for HER2-directed therapies (including monoclonal antibodies and ADCs), and discusses possible mechanisms of resistance.
Studied with: monoclonal antibodies, antibody-drug conjugates, chemotherapy.
Key findings
- HER2/neu coordinates cell growth and differentiation and when overexpressed and/or amplified its downstream tyrosine kinase can become constitutively activated, causing dysregulated gene transcription.
- HER2/neu has been successfully targeted in breast cancer with monoclonal antibodies and antibody-drug conjugates.
- Use of HER2-directed therapies in gynecologic malignancies has been slower, in part due to unique characteristics of HER2 protein expression and gene amplification in USC such as major heterogeneity and lack of apical staining compared to breast cancer.
- Optimal testing algorithms for HER2/neu status in USC may have important implications for developing targeted therapies.
- The review evaluates efficacy of HER2-directed therapies in both preclinical and clinical settings and discusses possible mechanisms of resistance.
Limitations: Narrative review rather than original experimental or systematic/meta-analytic data.; Abstract contains no quantitative results or study-level sample sizes.; Conclusions depend on heterogeneous preclinical and clinical studies in the literature rather than a single controlled dataset.; Field limitations noted (e.g., heterogeneity of HER2 expression in USC) may limit generalizability of testing and therapeutic approaches..
Reviews HER2/neu expression and the potential of HER2-directed therapies in uterine serous carcinoma, with attention to diagnostic testing and resistance.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 8
The American journal of surgical pathology · Apr 2025 · retrospective molecular cohort study
uterine serous carcinomaendometrial hyperplasia
Researchers identified 8 uterine serous carcinomas with concurrent endometrial hyperplasia and performed tumor-normal panel sequencing on the carcinoma and hyperplasia separately. In 7 of 8 paired cases the carcinoma and hyperplasia were clonally related and often shared TP53 mutations; one case was genetically unrelated and another shared only a single mutation. ARID1A mutations were more common in hyperplasia-associated USC than in atrophy-associated USC (43% vs 0%; P = 0.02).
Reported effects: cases_screened_with_sequencing_and_slides_available 267, n=267 · cases_with_sufficient_tissue_for_molecular_studies 8, n=8 · +5 more
Key findings
- Of 267 USCs with available sequencing and slides, 8 cases with concurrent carcinoma and hyperplasia had sufficient tissue for molecular study.
- In 7 of these 8 cases (87.5%), USC and hyperplasia were clonally related and shared multiple mutations.
- TP53 hotspot mutations were shared between carcinoma and hyperplasia in 4 cases (57% of the clonally related cases).
- In 1 case (USC4) the carcinoma and hyperplasia were genetically unrelated and the hyperplasia was TP53 wild-type.
- In another case (USC5) the carcinoma and TP53 wild-type hyperplasia shared 1 of 11 mutations and were distinct at the copy number level.
- ARID1A mutations were more prevalent in hyperplasia-associated USC than in atrophy-associated USC (43% vs. 0%; P = 0.02).
Limitations: Very small molecular cohort (only 8 cases with sufficient tissue) limits generalizability.; Retrospective selection of cases and requirement for sufficient tissue may introduce selection bias.; No functional experiments to demonstrate causality or biological consequences of shared mutations.; Clinical outcome data and broader validation cohorts are not reported in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMechanismMixed resultsLimited evidenceTier 4 · clinicaln = 95
Current oncology (Toronto, Ont.) · Apr 2025 · systematic review
uterine serous carcinoma
This systematic review searched PubMed/Medline and Cochrane through February 2025 and included 95 studies of uterine serous carcinomas. The authors report that these tumors are characterized by TP53 mutations and extensive copy number alterations and are commonly classified in the copy number-high/p53abn molecular group. The review identified 66 distinct molecular characteristics and new cancer signatures that may have prognostic significance and could inform tailored treatment strategies, though these findings require further validation.
Reported effects: included_studies 95 · distinct_molecular_characteristics 66
Key findings
- Uterine serous carcinomas are an aggressive minority of endometrial cancers.
- These tumors are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group.
- The systematic review searched PubMed/Medline and Cochrane databases through February 2025 and included 95 studies.
- A total of 66 distinct molecular characteristics and new cancer signatures with potential prognostic impact were identified across the included studies.
- Authors suggest these molecular findings may inform clinical practice and aid development of tailored treatment strategies for patients with uterine serous carcinoma.
Limitations: Review limited to English-language articles (English-only search was performed).; Systematic review format reported; no pooled meta-analytic effect sizes or patient-level pooled estimates are presented in the abstract.; Prognostic markers and new signatures identified across multiple studies may be heterogeneous and require independent validation before clinical application.; Abstract does not report the quality assessment of included studies or patient-level sample sizes..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 195
JCI insight · Apr 2025 · retrospective multiinstitutional cohort
uterine serous carcinomauterine neoplasm
Researchers scored GATA2 protein levels by immunohistochemistry in a retrospective cohort of 195 uterine serous carcinomas and related GATA2 levels to clinical outcomes. They found that FIGO stage I tumors with high GATA2 (GATA2hi) had 100% recurrence-free and 100% cancer-related survival, and among patients who omitted adjuvant chemotherapy, GATA2hi tumors had 100% 5-year recurrence-free survival versus 60% in GATA2lo tumors. In patient-derived USC cells, depletion of GATA2 increased invasion in vitro. The authors propose GATA2 IHC could identify a subgroup (~33%) of stage I patients with greatly reduced recurrence risk.
Reported effects: recurrence-free survival (FIGO stage I, GATA2hi) 100% · cancer-related survival (FIGO stage I, GATA2hi) 100% · +2 more
Key findings
- Patients with FIGO stage I GATA2hi USCs had 100% recurrence-free and 100% cancer-related survival, which was significantly better than patients with GATA2lo USCs.
- In patients for whom adjuvant chemotherapy was omitted, patients with GATA2hi USC had 100% recurrence-free 5-year survival compared with 60% recurrence-free survival in patients with GATA2lo USC.
- Depletion of GATA2 in patient-derived USC cells increased invasion in vitro.
- Routine GATA2 IHC identifies 33% of patients with FIGO stage I USC who have a greatly reduced risk of posthysterectomy USC recurrence.
Limitations: Retrospective cohort design (nonrandomized) limits causal inference and is susceptible to selection and unmeasured confounding.; Mechanistic data demonstrating increased invasion were limited to in vitro depletion of GATA2 in patient-derived cells (no in vivo validation).; Abstract does not report follow-up duration, subgroup sizes, confidence intervals, or p-values for the quoted percentages.; No prospective or external validation cohort reported in the abstract to confirm prognostic performance before clinical implementation..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text